Dr. Tang, as a key co-investigator, performs on several NIH R01 grants on the pathogenesis of childhood HIV-associated nephropathy (HIVAN), and including the role of heparin binding growth factors in vascular leakage and fatal bleeding. The performance of these projects includes independently applying the knowledge of the principles, theories and practices of toxicology and pharmaceuticals in the area of gene therapy, and using adenoviruses, lentiviruses and chicken viruses in transgenic animal models.
Dr. Tang has established novel models of hemangioma and angiosarcoma in several organs and blood vessel in TVA Tg-rats. He has used these models to evaluate the efficacy of chemicals and biologicals on vascular leakage. He has also uncovered the mutation of Apol 1 of potocytes (AJ & RW) from patients with HIVAN using genotyping; established Apol G0 & Apol G1 cell lines Tet-On Gene Expression System and transgenic mouse models and Chicken virus (RCASY-Apol G1/G0) induced system; and successfully tested Apol G/G0 expression in the potocytes and glomeruli of human and animal kidney by HIC and /or Western blot.
Dr. Tang has developed an Ad HIV-Tat-inducible model system for the generation of HIVAN in HIV-Tg mice and compiled data to prepare a manuscript This model was used to find the basic domain of HIV-tat transactivation protein to provide a molecular framework for developing novel therapies to improve the clinical outcome of children with HIVAN. Results were published in the Journal for the American Society of Nephrology in 2014.
Dr. Tang is interested in protein functional interaction, gene regulation and gene therapy and animal models, as well as safety assessment of biologicals. He has been serving as an editorial board member of reputed journals such as the Journal of Immunology and Vaccination, International Journal of HIV/AIDS and Research, and the JBR Journal of Translational Biomarkers & Diagnosis.